We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,192

Cleveland Clinic Decision Highlights Catch-22 Of Personalized Medicine Patents
  • Foley & Lardner LLP
  • USA
  • June 20 2017

The Federal Circuit decision in Cleveland Clinic Foundation v. True Health Diagnostics LLC, strikes another blow against the patent eligibility of


Supreme Court Biosimilar Patent Dance Decision Largely Favors Biosimilars
  • Foley & Lardner LLP
  • USA
  • June 13 2017

On June 12, 2017, the Supreme Court issued a unanimous decision in Sandoz Inc. v. Amgen Inc. (No. 15-1039), deciding that 42 U.S.C. 262(l)(9)(C


Industry Perspectives On The Biosimilar Patent Dance
  • Foley & Lardner LLP
  • USA
  • June 12 2017

The Supreme Court could issue its decision in the Amgen v. Sandoz biosimilar patent dance case any day now. Last week I participated in a panel


Supreme Court Decision Largely Favors Biosimilar Applicants
  • Foley & Lardner LLP
  • USA
  • June 12 2017

The U.S. Supreme Court rendered its first interpretations of the biosimilar patent dispute resolution procedures of the Biologics Price Competition


Supreme Court Finds Patent Rights Exhausted Overseas
  • Foley & Lardner LLP
  • USA
  • June 6 2017

In Impression Products, Inc. v. Lexmark International, Inc., the Supreme Court reversed the en banc decision of the Federal Circuit, and held U.S


Conflict Between Granting a Preliminary Injunction and Staying the Case Pending Appeal of the Injunction
  • Foley & Lardner LLP
  • USA
  • June 5 2017

In Fresenius Kabi USA, LLC v. Fera Pharmaceuticals, LLC, et al., Case No. 15-3654 (D.N.J.) the district court recently denied Fresenius’s motion to


What the Supreme Court’s Latest Patent Decision Means for Automotive Suppliers
  • Foley & Lardner LLP
  • USA
  • June 1 2017

Although U.S. patent law has long-established limits on enforcement after a Patented product has been sold, the technological innovations may put a


Court Questions Applicability of Function Way Result Test In Chemical Cases
  • Foley & Lardner LLP
  • USA
  • May 31 2017

In Mylan Institutional LLC v. Aurobindo Pharma Ltd., the Federal Circuit reviewed a preliminary injunction based in part on a finding of likelihood


Supreme Court Holds First Authorized Domestic or International Sale Exhausts U.S. Patent Rights
  • Foley & Lardner LLP
  • USA
  • May 31 2017

On May 30, 2017, the U.S. Supreme Court held in Impression Products, Inc. v. Lexmark International, Inc. that “patent exhaustion is uniform and


Recent Guidance from the Federal Circuit on the Doctrine of Equivalents in Cases Involving Chemical Compositions
  • Foley & Lardner LLP
  • USA
  • May 30 2017

In Mylan Institutional LLC, et al. V. Aurobindo Pharma Ltd., et al., Case No. 2017-1645, the Federal Circuit affirmed the district court’s grant of a